Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Algernon Pharmaceuticals Inc. (C:AGN)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for AGN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 13, 2020 08:00 ET
Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has reached 25% of its enrollment target for its Phase 2...
Read full article
Oct 09, 2020 08:00 ET
Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Mark Swaim, a former practicing physician and researcher has...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.36
--
--
Price to Sales - TTM
--
19.30
10.69
Price to Book - most recent quarter
2.39
4.20
2.91
Price to Cash Flow per share - TTM
--
14.47
11.47
Price to Free Cash Flow per share - TTM
--
49.82
21.27
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 30, 2020216,357-133,073
Sep 15, 2020349,430107,138
Aug 31, 2020242,292-245,959
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Algernon Pharmaceuticals Inc, formerly Breathtec Biomedical Inc, is a Canada-based drug development company. The Company is focused on the areas of nonalcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The Company's drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

See business summary

 

Twitter

Search (past week) for $AGN.CA

  • No tweets found